ContextVision AB (publ)

OB:CONTX Rapport sur les actions

Capitalisation boursière : NOK 267.9m

ContextVision Croissance future

Future contrôle des critères 3/6

ContextVision devrait augmenter ses bénéfices et son chiffre d'affaires de 55% et de 2% par an respectivement. Le BPA devrait croître de de 56.1% par an. Le rendement des capitaux propres devrait être 11.9% dans 3 ans.

Informations clés

55.0%

Taux de croissance des bénéfices

56.06%

Taux de croissance du BPA

Healthcare Services croissance des bénéfices22.7%
Taux de croissance des recettes2.0%
Rendement futur des capitaux propres11.90%
Couverture par les analystes

Low

Dernière mise à jour25 Feb 2026

Mises à jour récentes de la croissance future

ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target

Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target

Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00

Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00

Recent updates

CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI

Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.

CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI

Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.

CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects

Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.

CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects

Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.

CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside

Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.

CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook

Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).

CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook

Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).

CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook

Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.

CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook

Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.

CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook

Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.

CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside

Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.

More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%

Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%

CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance

Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.

ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target

Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target

We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings

Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings

Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00

Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00

Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence

The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).

This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts

May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts

There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings

Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
User avatar

Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence

Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.

Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%

Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%

Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?

Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?

There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings

Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings

ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear

Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear

ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)

Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)

When Should You Buy ContextVision AB (publ) (OB:CONTX)?

Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?

Prévisions de croissance des bénéfices et des revenus

OB:CONTX - Estimations futures des analystes et données financières antérieures (SEK Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20281181616231
12/31/20271161212191
12/31/2026113810161
12/31/2025111104N/A
9/30/2025109429N/A
6/30/20251169614N/A
3/31/2025120131926N/A
12/31/2024131252933N/A
9/30/2024135223030N/A
6/30/2024138263536N/A
3/31/2024138334243N/A
12/31/2023133334445N/A
9/30/2023135374044N/A
6/30/2023130364043N/A
3/31/2023128363640N/A
12/31/2022123332126N/A
9/30/2022117341825N/A
6/30/202211537915N/A
3/31/202210635-42N/A
12/31/20211003559N/A
9/30/2021945388N/A
6/30/202190421011N/A
3/31/202186351823N/A
12/31/202095381422N/A
9/30/20209981123N/A
6/30/202010010926N/A
3/31/202010313020N/A
12/31/2019957225N/A
9/30/20199514N/A22N/A
6/30/20199411N/A24N/A
3/31/2019935N/A11N/A
12/31/201891-1N/A5N/A
9/30/201885-2N/A5N/A
6/30/201882-3N/A5N/A
3/31/201882-2N/A4N/A
12/31/201781-2N/A2N/A
9/30/201783-1N/A5N/A
6/30/2017851N/A1N/A
3/31/2017810N/A4N/A
12/31/2016824N/A10N/A
9/30/2016763N/A6N/A
6/30/2016734N/A10N/A
3/31/2016725N/A12N/A
12/31/2015725N/A9N/A
9/30/2015705N/A9N/A
6/30/2015674N/A10N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CONTX ( 55% par an) est supérieure au taux d'épargne ( 3.1% ).

Bénéfices vs marché: Les bénéfices de CONTX ( 55% par an) devraient croître plus rapidement que le marché Norwegian ( 11.3% par an).

Croissance élevée des bénéfices: Les bénéfices de CONTX devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CONTX ( 2% par an) devrait croître plus lentement que le marché de Norwegian ( 2.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CONTX ( 2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de CONTX devrait être faible dans 3 ans ( 11.9 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/03 09:44
Cours de l'action en fin de journée2026/04/30 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

ContextVision AB (publ) est couverte par 3 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Juste SubataviciuteNorne Securities AS
Christian LeePareto Securities
Klas PalinRedeye